相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Denis Y. Logunov et al.
LANCET (2020)
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
Zacchaeus Anywaine et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Ebola vaccine trials: progress in vaccine safety and immunogenicity
Keesha M. Matz et al.
EXPERT REVIEW OF VACCINES (2019)
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens
Julien Nyombayire et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial
Jing-Xin Li et al.
LANCET GLOBAL HEALTH (2017)
An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates
Shipo Wu et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
Milagritos D. Tapia et al.
LANCET INFECTIOUS DISEASES (2016)
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
K. Ewer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prime-boost vaccine strategy against viral infections: Mechanisms and benefits
Kimia Kardani et al.
VACCINE (2016)
Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines
Shin-Hee Kim et al.
VIRUSES-BASEL (2016)
Adenoviral vector-based strategies against infectious disease and cancer
Chao Zhang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Feng-Cai Zhu et al.
LANCET (2015)
P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression
Wei Zhao et al.
JOURNAL OF GENERAL VIROLOGY (2015)
Newcastle Disease Virus (NDV) Recombinants Expressing Infectious Laryngotracheitis Virus (ILTV) Glycoproteins gB and gD Protect Chickens against ILTV and NDV Challenges
Wei Zhao et al.
JOURNAL OF VIROLOGY (2014)
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
Daphne A. Stanley et al.
NATURE MEDICINE (2014)
Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials
Stefania Capone et al.
EXPERT REVIEW OF VACCINES (2013)
Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates
Jason S. Richardson et al.
JOURNAL OF VIROLOGY (2013)
Generation and evaluation of a recombinant Newcastle disease virus expressing the glycoprotein (G) of avian metapneumovirus subgroup C as a bivalent vaccine in turkeys
Haixia Hu et al.
VACCINE (2011)
A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-Uninfected East Africans (RV 172)
Hannah Kibuuka et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Novel adenovirus vector-based vaccines for HIV-1
Dan H. Barouch
CURRENT OPINION IN HIV AND AIDS (2010)
Strategies to overcome host immunity to adenovirus vectors in vaccine development
Erin E. Thacker et al.
EXPERT REVIEW OF VACCINES (2009)
Assessment of the risk of Ebola virus transmission from bodily fluids and fomites
Daniel G. Bausch et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone
Carlos Estevez et al.
VIRUS RESEARCH (2007)
Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens
Joshua M. DiNapoli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
AI Freeman et al.
MOLECULAR THERAPY (2006)
Paramyxovirus mRNA editing, the 'rule of six' and error catastrophe: a hypothesis
D Kolakofsky et al.
JOURNAL OF GENERAL VIROLOGY (2005)
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
DH Barouch et al.
JOURNAL OF IMMUNOLOGY (2004)
Development of a preventive vaccine for Ebola virus infection in primates
NJ Sullivan et al.
NATURE (2000)
Newcastle disease and other avian paramyxoviruses
DJ Alexander
REVUE SCIENTIFIQUE ET TECHNIQUE-OFFICE INTERNATIONAL DES EPIZOOTIES (2000)
Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections
DA Martin et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2000)
分享论文
